PMH8 EQ-5D Analysis in Patients with Insomnia: Change of Quality of Life in Lemborexant Phase 3 Trial Sunrise 1

Ikeda, Satoshi; Azuma, Masumi; Fujimoto, Kazuma; Shibahara, Hidetoshi; Inoue, Sachi; Moline, Margaret; Ishii, Mikita

doi:10.1016/j.jval.2020.08.1086

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Utilities for responders were assumed to be the same as those for good sleepers whose utilities were equivalent to the values in the general population in Japan (Shiroiwa, 2016). According to the EuroQol 5-Dimensions (3-level version; EQ-5D-3L) data from SUNRISE 1, non-responders were assumed to experience utility decrement due to untreated insomnia (Ikeda et al, 2020). A total of 703 patients (responders: n = 116, non-responders: n = 587) who had sSOL responder rate data and who responded to the EQ-5D-3L questionnaire both at baseline and at one month were analyzed.…”

Section: Utilitiesmentioning

confidence: 99%

Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents

et al. 2022

View full text Add to dashboard Cite

Background Lemborexant has demonstrated statistically significant improvements in sleep onset and sleep maintenance compared with placebo and zolpidem tartrate extended release, measured both objectively using polysomnography and subjectively using sleep diaries, in the phase 3 clinical trial SUNRISE 1. This study evaluated the cost-effectiveness of lemborexant compared with suvorexant, zolpidem immediate release (IR), and untreated insomnia. Methods A decision-tree model was developed for falls, motor vehicle collisions, and workplace accidents associated with insomnia and insomnia treatments from a Japanese healthcare perspective and with a 6-month time horizon. The model extracted subjective sleep onset latency treatment responses and disutility values for non-responders from SUNRISE 1. Cost-effectiveness was assessed using incremental cost per quality-adjusted life year (QALY) gained. One-way and probabilistic sensitivity analyses were conducted to evaluate the impact of parameter uncertainty on the results. Results In the base-case analysis, the mean estimated QALYs for lemborexant, suvorexant, zolpidem-IR, and untreated insomnia were 0.4220, 0.4204, 0.4113, and 0.4163, and expected medical costs were JPY 34 034, JPY 38 371, JPY 38 139, and JPY 15 383, respectively. Lemborexant saved JPY 4337 and JPY 4105 compared with suvorexant or zolpidem-IR, respectively, while conferring QALY benefits. The incremental cost-effectiveness ratio (ICER) of lemborexant compared with that of untreated insomnia was JPY 3 220 975 /QALY. Lemborexant was dominant over suvorexant and zolpidem-IR and was cost-effective when compared with untreated insomnia. Sensitivity analyses supported the results' robustness. Conclusions In a Japanese clinical practice setting, lemborexant may represent a better investment for treating insomnia in the healthcare system in Japan.

show abstract

Section: Utilitiesmentioning

confidence: 99%